CSTL CFO sells 5,388 shares at $35.08; holds 43,328 shares

Castle Biosciences (CSTL) Form 4: Chief Financial Officer Frank Stokes reported an open-market sale of 5,388 shares of common stock on 11/11/2025 at a weighted-average price of $35.08.

Rhea-AI Filing Summary

Castle Biosciences (CSTL) Form 4: Chief Financial Officer Frank Stokes reported an open-market sale of 5,388 shares of common stock on 11/11/2025 at a weighted-average price of $35.08. The filing notes multiple trades executed between $34.44 and $35.37. Following the transaction, Stokes beneficially owns 43,328 shares, held directly. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on 08/12/2025.

Insights

Governance and insider activity analyst

Routine 10b5-1 insider sale; administrative disclosure.

The CFO of Castle Biosciences disclosed selling 5,388 shares at a $35.08 weighted-average on 11/11/2025. The transaction occurred under a pre-established Rule 10b5-1 plan adopted on 08/12/2025, which automates trades under preset conditions.

Such filings document insider activity and do not, by themselves, indicate a change in business fundamentals. After the sale, the officer reports 43,328 shares beneficially owned, directly. The price range disclosed spans $34.44 to $35.37, reflecting execution across multiple trades.

Insider Trade Summary

Net Seller: 5,388 shares

Net Sell 1 txn

Insider Stokes Frank

Role Chief Financial Officer

Sold 5,388 shs ($189K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,388	$35.08	$189K

Holdings After Transaction: Common Stock — 43,328 shares (Direct)

Footnotes (2)

1. F1. The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Frank Stokes on August 12, 2025
2. F2. This transaction was executed in multiple trades at prices ranging from $34.44 to $35.37, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CSTL's CFO report in the latest Form 4?

A sale of 5,388 shares of common stock on 11/11/2025 at a $35.08 weighted-average price.

Is the CSTL insider sale under a Rule 10b5-1 plan?

Yes. The sale was made pursuant to a Rule 10b5-1 plan adopted on 08/12/2025.

What is the remaining stake of the CSTL CFO after the sale?

Following the transaction, the CFO beneficially owns 43,328 shares, held directly.

What was the execution price range for the CSTL insider sale?

Trades were executed between $34.44 and $35.37, with a $35.08 weighted-average.

Who is the reporting person in this CSTL Form 4 filing?

The reporting person is Frank Stokes, Chief Financial Officer of Castle Biosciences.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/13/2025 - 04:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stokes Frank

(Last) (First) (Middle)

C/O CASTLE BIOSCIENCES, INC.

505 S. FRIENDSWOOD DRIVE, SUITE 401

(Street)

FRIENDSWOOD TX 77546

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CASTLE BIOSCIENCES INC [ CSTL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/11/2025		S(1)		5,388	D	$35.08(2)	43,328	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Frank Stokes on August 12, 2025

2. This transaction was executed in multiple trades at prices ranging from $34.44 to $35.37, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ Frank Stokes, Attorney-in-fact	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.